Clinical Trials Sponsored by Biomerix

Total 201 results

Biomerix

Unknown

Study of Surgical Mesh for Inguinal Hernia Repair

Hernia, Inguinal

United States
Xenova Biomedix

Withdrawn

Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

Glioblastoma Multiforme

United States, Australia
Biomerica

Completed

Endpoint Determination Study Protocol

Irritable Bowel Syndrome

United States
Biomerica

Completed

Specimen Collection Study for H. Pylori Testing

Helicobacter Infections

United States
Biomerica

Completed

Specimen Collection Study Protocol

Focus in on Collecting Paired Specimens for Matrix Equivalency

United States
KC BioMediX, Inc

Completed

Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance

Preterm Birth

United States
KC BioMediX, Inc

Completed

Comparison of Non-nutritive Suck (NNS) Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants

Preterm Birth

United States
KC BioMediX, Inc

Completed

Oral Entrainment on Suck Development of Preterm Infants Born 23 to 34 Weeks Gestational Age (GA)

Preterm Birth

United States
BioMarin Pharmaceutical

Recruiting

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

Phenylketonuria (PKU)

United States
Biodesix, Inc.

Recruiting

Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules (ALTITUDE)

Non-small Cell Carcinoma | Nodule Solitary Pulmonary

United States, Canada
BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
BioMarin Pharmaceutical

Completed

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (GENEr8-2)

Hemophilia A

United States
BioMarin Pharmaceutical

Completed

Kuvan®'s Effect on the Cognition of Children With Phenylketonuria (KOGNITO)

Phenylketonuria

Italy, Spain, United Kingdom, Germany
BioMarin Pharmaceutical

Completed

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency (KAMPER)

Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency

Sweden, France, Italy, Spain, Germany, Netherlands, Austria, Slovakia, Portugal
BioMarin Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Achondroplasia

United States, Australia, Germany, Spain, United Kingdom, Japan, Turkey
BioMarin Pharmaceutical

Completed

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

United States, France, Australia, Germany, Ireland, Austria, Belgium, Italy, Lithuania, Netherlands, Portugal, Sweden, United Kingdom
BioMarin Pharmaceutical

Completed

Lifetime Impact Study for Achondroplasia (LISA)

Achondroplasia

Argentina, Brazil, Colombia
BioMarin Pharmaceutical

Completed

Lifetime Impact of Achondroplasia Study in Europe-LIAISE (LIAISE)

Achondroplasia

Spain, Denmark, Italy, Austria, Germany, Sweden
BioMarin Pharmaceutical

Completed

A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease

Sickle Cell Disease

United States
BioMarin Pharmaceutical

Completed

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

Intermittent Claudication

United States, Argentina
BioMarin Pharmaceutical

Completed

Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Italy, Sweden
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
BioMarin Pharmaceutical

Terminated

Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Netherlands, Belgium, Italy, Sweden
BioMarin Pharmaceutical

No longer available

Extension Study of Drisapersen in DMD Subjects

Duchenne Muscular Dystrophy

United States, Germany, United Kingdom, Japan, Netherlands, France, Spain, Korea, Republic of, Italy, Belgium, Taiwan, Argentina, Australia, Bulgaria, Czechia, Israel, Norway, Poland, Russian Federation, Turkey
BioMarin Pharmaceutical

Terminated

A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United Kingdom, Italy, Belgium, Netherlands, France
BioMarin Pharmaceutical

Completed

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Phenylketonuria

United States, Canada
BioMarin Pharmaceutical

Terminated

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United Kingdom, United States, Germany
BioMarin Pharmaceutical

Terminated

A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVA

United Kingdom
BioMarin Pharmaceutical

Completed

Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Phenylketonurias

United States
BioMarin Pharmaceutical

Completed

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

MPS IV A

United States, Canada, France, United Kingdom, Taiwan, Argentina, Colombia, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, Germany, Portugal, Italy, Qatar
BioMarin Pharmaceutical

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

MPS IV A

United Kingdom
BioMarin Pharmaceutical

Completed

Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02

MPS VI

United States, Australia, France, Brazil, Germany, Portugal, United Kingdom
BioMarin Pharmaceutical

Completed

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

Phenylketonurias

United States
BioMarin Pharmaceutical

Completed

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

Hypertension

United States
BioMarin Pharmaceutical

Approved for marketing

Sapropterin Expanded Access Program

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria

Phenylketonurias

United States
BioMarin Pharmaceutical

Recruiting

A Study to Assess Growth in Children With Idiopathic Short Stature

Idiopathic Short Stature

United States
BioMarin Pharmaceutical

Recruiting

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace) (PALace)

Phenylketonuria (PKU)

United States, Germany, Italy
BioMarin Pharmaceutical

Recruiting

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors (GENEr8-INH)

Hemophilia A With Inhibitor | Hemophilia A With Anti Factor VIII

United States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
BioMarin Pharmaceutical

Completed

A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A (SAAVY)

Hemophilia A

United States
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

Hemophilia A

United States, Australia, Taiwan, Brazil
Biodesix, Inc.

Active, not recruiting

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

Non-Small Cell Lung Cancer

United States
BioMarin Pharmaceutical

Active, not recruiting

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Achondroplasia

United States, Australia, Japan, United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Achondroplasia

Australia, United Kingdom
Biodesix, Inc.

Active, not recruiting

A Registry to Evaluate the Performance of the BDX-XL2 Test (ORACLE)

NSCLC | Nodule Solitary Pulmonary

United States
BioMarin Pharmaceutical

Active, not recruiting

AAV Gene Therapy Study for Subjects With PKU

Phenylketonuria (PKU)

United States, United Kingdom
BioMarin Pharmaceutical

Completed

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IV A

United States, Canada, France, Taiwan, Argentina, Colombia, Spain, Turkey, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, United Kingdom, Germany, Norway, Portugal, Italy, Qatar

Clinical Trials Sponsored by Biomerix

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations